Evidence map›Paper›PMID 31429928›Full record

ArticleBiotechnology and bioengineering2019

Escherichia coli "TatExpress" strains export several g/L human growth hormone to the periplasm by the Tat pathway.

Isabel Guerrero Montero, Kirsty L Richards, Chillel Jawara, Douglas F Browning, Amber R Peswani, Mickael Labrit, Matthew Allen, Cedric Aubry, Emma Davé, David P Humphreys and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology and bioengineering, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Strategies to Enhance Periplasmic Recombinant Protein Production Yields inFrontiers in bioengineering and biotechnology · 2021
    Review
  9. Evolution ofInternational journal of molecular sciences · 2020
    Review
  10. Article
  11. An Engineered Pathway for Production of Terminally SialylatedFrontiers in bioengineering and biotechnology · 2020
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Isabel Guerrero MonteroSchool of Biosciences, University of Kent, Canterbury, United Kingdom.
Kirsty L RichardsSchool of Biosciences, University of Kent, Canterbury, United Kingdom.
Chillel JawaraSchool of Biosciences, University of Kent, Canterbury, United Kingdom.
Douglas F BrowningSchool of Biosciences, Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Amber R PeswaniSchool of Biosciences, University of Kent, Canterbury, United Kingdom.
Mickael LabritDiscovery Biology, UCB Celltech, Slough, United Kingdom.
Matthew AllenDiscovery Biology, UCB Celltech, Slough, United Kingdom.
Cedric AubryDiscovery Biology, UCB Celltech, Slough, United Kingdom.
Emma DavéDiscovery Biology, UCB Celltech, Slough, United Kingdom.
David P HumphreysDiscovery Biology, UCB Celltech, Slough, United Kingdom.
Stephen J W BusbySchool of Biosciences, Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Colin RobinsonSchool of Biosciences, University of Kent, Canterbury, United Kingdom.ORCID 0000-0002-1739-032X
UCB Pharma (United Kingdom) · GBUniversity of Kent · GBUniversity of Birmingham · GB

Funding

Biotechnology and Biological Sciences Research Council BB/L013770/1Biotechnology and Biological Sciences Research Council BB/M018288/1Biotechnology and Biological Sciences Research Council BB/P02789X/1
6 · The paper itself

Abstract

Escherichia coli is a heavily used platform for the production of biotherapeutic and other high-value proteins, and a favored strategy is to export the protein of interest to the periplasm to simplify downstream processing and facilitate disulfide bond formation. The Sec pathway is the standard means of transporting the target protein but it is unable to transport complex or rapidly folding proteins because the Sec system can only transport proteins in an unfolded state. The Tat system also operates to transport proteins to the periplasm, and it has significant potential as an alternative means of recombinant protein production because it transports fully folded proteins. Here, we have tested the Tat system's full potential for the production of biotherapeutics for the first time using fed-batch fermentation. We expressed human growth hormone (hGH) with a Tat signal peptide in E. coli W3110 "TatExpress" strains that contain elevated levels of the Tat apparatus. This construct contained four amino acids from TorA at the hGH N-terminus as well as the initiation methionine from hGH, which is removed in vivo. We show that the protein is efficiently exported to the periplasm during extended fed-batch fermentation, to the extent that it is by far the most abundant protein in the periplasm. The protein was shown to be homogeneous, disulfide bonded, and active. The bioassay showed that the yields of purified periplasmic hGH are 5.4 g/L culture whereas an enzyme-linked immunosorbent assay gave a figure of 2.39 g/L. Separate analysis of a TorA signal peptide linked to hGH construct lacking any additional amino acids likewise showed efficient export to the periplasm, although yields were approximately two-fold lower.

Indexed as

Protein FoldingProtein Sorting SignalsEscherichia coliHuman Growth HormoneHumansPeriplasmRecombinant Fusion ProteinsHuman Growth HormoneProtein Sorting SignalsRecombinant Fusion ProteinsbiopharmaceuticalsE. coliprotein secretionrecombinant proteinTat system

Identifiers

PMID31429928
PMCPMC6907408
OpenAlexW2969640842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.